Frontiers in cardiovascular medicine · 2026
A retrospective observational study of clinical presentation and management outcomes in patients with paroxysmal supraventricular tachycardia at a tertiary center in Bahrain.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zeidan Osama, Alohaly Aljazi, Zayer Ali, Jaragh Noor, Alqayem Maryam, Ziedan Ayat, Fredericks Salim, Assar Walid
Аннотация
OBJECTIVES: This study aimed to evaluate the clinical characteristics, symptom presentation, and management outcomes of patients diagnosed with paroxysmal supraventricular tachycardia (PSVT) at King Hamad University Hospital (KHUH), a tertiary care center. It examined the influence of demographics, comorbidities, and sex on treatment responses to pharmacologic and non-pharmacologic interventions, including cardioversion.
METHODS: A retrospective observational study was conducted on 427 adult patients with PSVT (ICD-10: I47.1, confirmed by chart review) between January 2018 and early 2024. Data were extracted from the KHUH HOPE electronic medical records system. Descriptive statistics summarized baseline characteristics; chi-square tests examined categorical associations. Kaplan-Meier analyses for the cardioversion subgroup (n = 18) are presented as exploratory and descriptive only.
RESULTS: Females comprised 56.9% of the cohort (mean age 52.8 ± 15.2 years). Palpitations were the most common symptom (94.4%). Of 219 patients who received adenosine, 177 (80.8%) achieved cardioversion with the first dose, 25 (11.4%) with the second, and 17 (7.8%) with the third. Vagal maneuvers showed reduced success in patients with structural heart disease and diabetes mellitus. Electrical cardioversion was required in 18 patients (4.2%). Pacemaker implantation was documented in 3 patients (0.7%) for co-existing conduction disease, not as a PSVT treatment. Comorbidities significantly influenced outcomes: hypertension was associated with favorable vagal maneuver response, while heart failure and ischemic heart disease correlated with poor response across all modalities.
CONCLUSION: PSVT generally responds well to first-line treatments. However, individualized strategies are warranted for patients with structural heart disease or significant comorbidities. Observed sex-based and age-related response differences are descriptive and require multivariable validation.
METHODS: A retrospective observational study was conducted on 427 adult patients with PSVT (ICD-10: I47.1, confirmed by chart review) between January 2018 and early 2024. Data were extracted from the KHUH HOPE electronic medical records system. Descriptive statistics summarized baseline characteristics; chi-square tests examined categorical associations. Kaplan-Meier analyses for the cardioversion subgroup (n = 18) are presented as exploratory and descriptive only.
RESULTS: Females comprised 56.9% of the cohort (mean age 52.8 ± 15.2 years). Palpitations were the most common symptom (94.4%). Of 219 patients who received adenosine, 177 (80.8%) achieved cardioversion with the first dose, 25 (11.4%) with the second, and 17 (7.8%) with the third. Vagal maneuvers showed reduced success in patients with structural heart disease and diabetes mellitus. Electrical cardioversion was required in 18 patients (4.2%). Pacemaker implantation was documented in 3 patients (0.7%) for co-existing conduction disease, not as a PSVT treatment. Comorbidities significantly influenced outcomes: hypertension was associated with favorable vagal maneuver response, while heart failure and ischemic heart disease correlated with poor response across all modalities.
CONCLUSION: PSVT generally responds well to first-line treatments. However, individualized strategies are warranted for patients with structural heart disease or significant comorbidities. Observed sex-based and age-related response differences are descriptive and require multivariable validation.